• Home
  • Resources
    • News & Events
    • Compliance
    • Medical Information
    • Careers
  • Contact Us
Azurity Pharmaceuticals
  • Company
    • About Us
    • Company Culture
    • Management Team
    • Board of Directors
  • FDA-Approved Products
  • Non-FDA Approved FIRST® Compounding Kits
Select Page

AZURITY RESPONSE TO COVID-19

AZURITY PHARMACEUTICALS? RESPONSE TO T HE CORONAVIRUS (COVID-19) PANDEMIC

Home

 

Company

About Us
Company Culture
Management Team
Board of Directors

  • Follow
  • Follow

FDA-Approved Products

FIRVANQ® | Epaned® | Qbrelis® | Katerzia® | Xatmep®

Non-FDA Approved FIRST® Compounding Kits

Portfolio of Kits

Resources

News & Events
Compliance
Medical Information
Careers

Contact Us

Terms of Use | Privacy Policy and Cookie Notice

Azurity Pharmaceuticals, Inc. was formerly known as known as CutisPharma, Inc., parent company of Silvergate Pharmaceuticals, Inc. Product labeling, packaging, and imagery are for representation purposes only and may reflect Azurity, CutisPharma, or Silvergate.

The Information contained herein, including product information, is intended only for residents of the United States.

© 2019-2020 Azurity Pharmaceuticals, Inc. All Rights Reserved. All Trademarks referred to are the property of their respective owners. WEB-AZ-2.0
azurity-logo-white-rpng-2